Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

@article{Schrezenmeier2020MechanismsOA,
  title={Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology},
  author={E. Schrezenmeier and T. D{\"o}rner},
  journal={Nature Reviews Rheumatology},
  year={2020},
  volume={16},
  pages={155-166}
}
Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and other inflammatory rheumatic diseases, insights into the mechanism of action of these drugs are still emerging. Hydroxychloroquine and chloroquine are weak bases and have a characteristic ‘deep’ volume of distribution and a half-life of around 50 days. These drugs interfere with lysosomal activity and autophagy… Expand

Paper Mentions

Interventional Clinical Trial
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label… Expand
ConditionsAlport Syndrome, X-Linked
InterventionDrug
Interventional Clinical Trial
This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19  
ConditionsCOVID-19
InterventionDrug
Hydroxychloroquine in rheumatic autoimmune disorders and beyond
TLDR
The current knowledge on the molecular modes of action of these drugs and the circumstances under which they trigger side effects are reviewed, of particular importance as the therapeutic use of HCQ is expanding beyond the treatment of malaria and RADs. Expand
The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
TLDR
Evidence has shown that these structures are leader molecules that can be modified or combined with other therapeutic agents, and the use of these antimalarial drugs on diseases. Expand
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
TLDR
Although these treatments could be an interesting potential strategy to limit progression toward uncontrolled inflammation, they do not appear per se sufficiently potent to control the whole inflammatory process in COVID-19, and more targeted and/or potent therapies should be required at least in add-on. Expand
Side Effects of Chloroquine and HydroxychloroquineExamined on Ants as Models
TLDR
The side effects of chloroquine and hydroxychloroquine on ants as models found that they impacted their food consumption, activity, audacity, tactile perception, social relationships, cognition, and that no adaptation occurred to these adverse effects, and no dependence occurred. Expand
Chloroquine cardiac effects and toxicity.A short update.
  • K. Mubagwa
  • Medicine
  • International Journal of Antimicrobial Agents
  • 2020
TLDR
The antimalarials chloroquine and hydroxychloroquine are used for the treatment of other diseases, including cancer and viral infections such as COVID-19, but risks of cardiotoxic effects tend to limit their use. Expand
Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic
TLDR
The difference between chloroquine (CQ/hydroxychloroquine) use, activity, recommendation, doses, and adverse effects on two groups of patients: those with rheumatic and viral diseases (including COVID-19). Expand
Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy
TLDR
The immunomodulatory activity of hydroxychloroquine and chloroquine is explored, their impact on viral infections, and their potential to improve the efficacy and safety of retinal gene therapy by reducing AAV-induced immune responses are explored. Expand
Rethinking the role of hydroxychloroquine in the treatment of COVID‐19
TLDR
Data informed opinion is rendered that hydroxychloroquine and chloroquine should be used with caution and in the context of carefully thought out clinical trials, or on a case‐by‐case basis after rigorous consideration of the risks and benefits of this therapeutic approach. Expand
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoingExpand
Repurposing New Use for Old Drug Chloroquine against Metabolic Syndrome: A Review on Animal and Human Evidence
  • Sok Kuan Wong
  • Medicine
  • International journal of medical sciences
  • 2021
TLDR
The current state of knowledge supported the repurposing of CQ and HCQ usage in the management of MetS. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 222 REFERENCES
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
TLDR
This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, HCQ and CQ, in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA). Expand
Hydroxychloroquine in systemic lupus erythematosus (SLE)
TLDR
Hydroxychloroquine may offer several advantages not only in patients with mild SLE but can also exert important beneficial effects in lupus patients with organ involvement and in pregnant women, which should encourage a larger use of HCQ. Expand
The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine
TLDR
Competition with proton pump inhibitors and/or a higher pH would inhibit the accumulation of chloroquine/hydroxychloroquine at their site of action, hence mitigating the immunomodulatory effects of these agents. Expand
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
TLDR
High levels of evidence were found that AMs prevent lupus flares and increase long-term survival of patients with SLE; moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss and evidence supporting an effect on severe l upus activity, lipid levels and subclinical atherosclerosis was weak. Expand
Antimalarial drugs in systemic lupus erythematosus: use in pregnancy.
TLDR
It is the opinion that the 4-aminoquinoline radical containing antimalarial drugs should not be discontinued during pregnancy in a patient with lupus, particularly when the known terminal elimination half life is 1 to 2 months. Expand
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE
TLDR
Hydroxychloroquine is a platelet inhibitor and appears to decrease the risk of thromboembolism in patients with anticardiolipin antibodies and is associated with lower serum cholesterol and low-density lipoprotein levels compared to those present in patients who are taking corticosteroids but not antimalarials for SLE. Expand
Population Pharmacokinetics of Hydroxychloroquine in Patients With Rheumatoid Arthritis
TLDR
A population PK model was successfully developed for HCQ, and steady-state drug concentrations and maintenance dosage requirements were similar, and the population estimate of bioavailability of 0.75 was consistent with literature values. Expand
A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role
TLDR
A case of a young woman with type 1 diabetes whose glycemic control was optimized with the introduction of HCQ as a treatment for her Sjogren syndrome in addition to a subtle yet measurable improvement in her lipid profile is described. Expand
Influence of hydroxychloroquine on the bioavailability of oral metoprolol.
TLDR
HCQ inhibits metoprolol metabolism most probably by inhibiting its biotransformation by CYP2D6, except in an individual with limited CYP1D6 capacity. Expand
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
TLDR
There is a weak, but predictable, relationship between blood DHCQ concentrations and efficacy of treatment with HCQ, and there is an association between gastrointestinal adverse events and elevated blood HCQ concentrations. Expand
...
1
2
3
4
5
...